-
Something wrong with this record ?
Dapsone treatment is efficient against persistent cutaneous and gastrointestinal symptoms in children with Henoch-Schönlein purpura
J. Volejnikova, J. Horacek, F. Kopriva
Language English Country Czech Republic
Document type Case Reports, Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
29097818
DOI
10.5507/bp.2017.044
Knihovny.cz E-resources
- MeSH
- Skin Diseases, Bacterial drug therapy MeSH
- Chlamydophila pneumoniae MeSH
- Dapsone therapeutic use MeSH
- Child MeSH
- Gastrointestinal Diseases drug therapy MeSH
- IgA Vasculitis complications MeSH
- Chlamydophila Infections complications MeSH
- Humans MeSH
- Adolescent MeSH
- Mycoplasma pneumoniae MeSH
- Pneumonia, Mycoplasma complications MeSH
- Child, Preschool MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
BACKGROUND: Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and by the deposition of IgA immune complexes. An association between HSP and atypical bacteria is uncommon in children. METHODS AND RESULTS: Here we report three cases of children, aged 5, 4 and 16 years, who were diagnosed with HSP associated with Mycoplasma pneumoniae or Chlamydia pneumoniae infection. In all presented cases, persistent cutaneous manifestations and abdominal pain were resistant to antibiotics and corticosteroids, but resolved during 48 h after the introduction of dapsone. No adverse effects of treatment were observed. CONCLUSION: Dapsone, a sulphone with an anti-inflammatory activity, showed remarkable therapeutic efficacy against rash and gastrointestinal symptoms in children with HSP. Its administration should be considered particularly in persistent cutaneous form of HSP.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18038666
- 003
- CZ-PrNML
- 005
- 20181203081700.0
- 007
- ta
- 008
- 181123s2018 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2017.044 $2 doi
- 035 __
- $a (PubMed)29097818
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Volejníková, Jana, $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic $d 1981- $7 xx0105026
- 245 10
- $a Dapsone treatment is efficient against persistent cutaneous and gastrointestinal symptoms in children with Henoch-Schönlein purpura / $c J. Volejnikova, J. Horacek, F. Kopriva
- 520 9_
- $a BACKGROUND: Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and by the deposition of IgA immune complexes. An association between HSP and atypical bacteria is uncommon in children. METHODS AND RESULTS: Here we report three cases of children, aged 5, 4 and 16 years, who were diagnosed with HSP associated with Mycoplasma pneumoniae or Chlamydia pneumoniae infection. In all presented cases, persistent cutaneous manifestations and abdominal pain were resistant to antibiotics and corticosteroids, but resolved during 48 h after the introduction of dapsone. No adverse effects of treatment were observed. CONCLUSION: Dapsone, a sulphone with an anti-inflammatory activity, showed remarkable therapeutic efficacy against rash and gastrointestinal symptoms in children with HSP. Its administration should be considered particularly in persistent cutaneous form of HSP.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a infekce bakteriemi rodu Chlamydophila $x komplikace $7 D023521
- 650 _2
- $a Chlamydophila pneumoniae $7 D016993
- 650 _2
- $a dapson $x terapeutické užití $7 D003622
- 650 _2
- $a gastrointestinální nemoci $x farmakoterapie $7 D005767
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Mycoplasma pneumoniae $7 D009177
- 650 _2
- $a mykoplazmová pneumonie $x komplikace $7 D011019
- 650 _2
- $a IgA vaskulitida $x komplikace $7 D011695
- 650 _2
- $a bakteriální nemoci kůže $x farmakoterapie $7 D017192
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Horáček, Jaroslav, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic $d 1941- $7 ola2002110040
- 700 1_
- $a Kopřiva, František, $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic $d 1956- $7 xx0012473
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 162, č. 2 (2018), s. 154-158
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29097818 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20181123 $b ABA008
- 991 __
- $a 20181128142028 $b ABA008
- 999 __
- $a ok $b bmc $g 1356015 $s 1035705
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 162 $c 2 $d 154-158 $e 20171102 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20181123
